Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration
暂无分享,去创建一个
A. Masson-Lecomte | F. Montorsi | A. Minervini | T. Klatte | P. Umari | A. Briganti | S. Shariat | C. Fankhauser | W. Krajewski | M. Rouprêt | M. Borghesi | A. Necchi | P. Gontero* | F. Soria | M. Moschini | M. Rink | C. Simeone | R. Contieri | R. Hurle | R. Colombo | A. Mattei | P. Baumeister | J. Teoh | M. Roumiguié | E. Laukhtina | C. Lonati | A. Mari | G. Schulz | S. Zamboni | L. Afferi | K. Hendricksen | A. Antonelli | G. Marra | A. Valiquette | M. C. Mir | A. Martini | R. Carando | A. Bajeot | S. Einerhand | P. Gontero
[1] C. Stief,et al. Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy? , 2020, World Journal of Urology.
[2] M. Roscigno,et al. The impact of histological variants on outcomes after open radical cystectomy for muscle-invasive urothelial bladder cancer: results from a single tertiary referral centre , 2020, World Journal of Urology.
[3] M. Babjuk,et al. Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. , 2020, European urology focus.
[4] F. Saad,et al. Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study , 2020, World Journal of Urology.
[5] F. Saad,et al. Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[6] J. Witjes,et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.
[7] M. Galsky,et al. What Is the Significance of Variant Histology in Urothelial Carcinoma? , 2020, European urology focus.
[8] M. Babjuk,et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. , 2019, European urology.
[9] U. Capitanio,et al. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. , 2019, European urology.
[10] W. Oyen,et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Shahrokh F. Shariat,et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. , 2019, European urology.
[12] Junghoon Lee,et al. BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants , 2019, Scientific Reports.
[13] M. Meng,et al. Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. , 2018, Clinical genitourinary cancer.
[14] Tetsuya Shindo,et al. Bacillus Calmette-Guérin may have clinical benefit for glandular or squamous differentiation in non-muscle invasive bladder cancer patients: retrospective multicenter study , 2018, Japanese journal of clinical oncology.
[15] M. Amin,et al. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. , 2018, European Urology.
[16] L. Kiemeney,et al. Smoking intensity and bladder cancer aggressiveness at diagnosis , 2018, PloS one.
[17] P. Capogrosso,et al. Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer. , 2016, European urology focus.
[18] A. Briganti,et al. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder , 2016, Nature Reviews Urology.
[19] P. Humphrey,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.
[20] G. Hidas,et al. The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer , 2016, Front. Oncol..
[21] M. Colecchia,et al. Usefulness of pT1 substaging in papillary urothelial bladder carcinoma , 2016, Diagnostic Pathology.
[22] S. Porten,et al. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer , 2014, Current opinion in urology.
[23] W. Lowrance,et al. Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. , 2011, The Journal of urology.
[24] M. Duvdevani,et al. Is radical cystectomy mandatory in every patient with variant histology of bladder cancer , 2011, Rare tumors.
[25] U. Capitanio,et al. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. , 2009, The Journal of urology.
[26] E. Messing,et al. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? , 2009, Urology.
[27] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[28] E. Spitznagel,et al. ASA Physical Status Classifications: A Study of Consistency of Ratings , 1978, Anesthesiology.